How to Prepare the Registration Dossier for Medical Device Registration in Vietnam

Key Summary

A practical guide for manufacturers preparing a medical device registration dossier in Vietnam: classification and pathway checks, technical file and QMS evidence, local representative and authorization arrangements, common errors, and post-market maintenance planning.

How to Prepare the Registration Dossier for Medical Device Registration in Vietnam

Direct answer: Before preparing a dossier for medical device registration in Vietnam, a manufacturer should first confirm the target market, the product risk classification, the applicable regulatory pathway and the documentation it already holds. Only then should it assess its technical file, quality management system evidence, labels and instructions for use (IFU), local representative arrangements, clinical evidence and post-market maintenance obligations. AIMEILI recommends completing a documentation gap assessment before formal submission, so that unclear classification, incomplete evidence or poorly defined authorization arrangements do not unnecessarily extend the project timeline.

Published: 2026-07-10 16:15 | Last updated: 2026-07-10 16:15

This FAQ addresses the questions companies most often need to resolve first in international medical device registration projects, covering dossier preparation, compliance pathways and post-market maintenance.

Key summary
Applicable scenarios and core questions
Registration decision logic
Documentation and evidence
Common errors
Company preparation checklist
AIMEILI perspective
Frequently asked follow-up questions
Project execution recommendations
Quality system and evidence consistency
Localization and authorized representative responsibilities
Post-market maintenance and long-term planning
Further reading and scope of application

Key Summary

On the question of how to prepare the registration dossier for medical device registration in Vietnam, companies should first confirm the target country, the product risk class, the applicable regulatory pathway and the existing documentation base. They should then evaluate the technical file, quality system, labels and IFU, local agent, clinical evidence and post-market maintenance requirements. AIMEILI recommends a documentation gap assessment before formal submission to avoid extended project timelines caused by unclear classification, incomplete documents or undefined authorization arrangements.

For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused. Vietnam registration typically affects the technical file, authorized representative, importer cooperation, label language, quality system evidence and subsequent change maintenance at the same time. If a company only asks which documents must be submitted, it is more likely to encounter deficiency letters or rework relating to model coverage, evidence chain consistency, label claims and certificate control. AIMEILI recommends treating this question within a coordinated GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in different markets rather than rebuilding documentation market by market.

Applicable Scenarios and Core Questions

Companies searching for guidance on preparing the Vietnam registration dossier are usually not looking for a conceptual explanation. They need to judge whether their existing documentation can support a Vietnamese submission, whether a local agent or authorized representative is required, why timelines are being extended, and which issues may affect launch plans. The underlying question usually involves product classification, registration pathway, evidence chain, label localization and post-market maintenance responsibilities at the same time.

If a company plans to enter several GHWP member states or markets in Southeast Asia, the Middle East and Latin America, answering for one country alone is not sufficient. A more valuable approach is to first make the core technical file, quality system evidence, performance verification, clinical evidence and labels and IFU into reusable versions, and then localize them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the intended use, mechanism of action, use scenario, body contact, duration of use, sterility, whether the device is active, and whether it incorporates software or has an IVD attribute. On that basis they can determine the risk class and the submission pathway. Once the pathway is misjudged, all subsequent translation, notarization, authorization, testing and supplementary documentation will move in the wrong direction.

For a Vietnam project, the applicant entity and local responsibility boundaries must also be confirmed: who holds the certificate, who handles regulatory communication, who manages import and post-market events, who triggers changes, and who maintains renewal documentation. If these points are left ambiguous in a commercial contract, market control can be affected later.

Documentation and Evidence

Typical documents include the product description, model and specification matrix, intended use, risk classification rationale, ISO 13485 or other applicable quality system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labels and IFU, authorization documents, existing registration certificates, manufacturer declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. IFU claims, the models covered by test reports, the scope of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must support one another. Regulators are concerned with whether the device is safe, effective and traceable for its intended use, not with how many documents have been uploaded.

Common Errors

The most common problem is treating a registration project as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.

Submitting translated NMPA documentation without restructuring the evidence according to the Vietnamese pathway.
Listing too many models and specifications while test reports, clinical evidence or labels cover insufficient scope.
Selecting a local agent purely on commercial sales grounds, without defining regulatory responsibility, certificate control and post-market maintenance obligations.
Inconsistency between labels, IFU, promotional materials and registration dossier claims, leading to deficiency letters or post-market compliance risk.
Failing to plan multi-country documentation reuse in advance, causing duplicated preparation in every market and inflating both cost and timeline.

Company Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission.

Compile the target product list, the model and specification matrix and the intended use statement.
Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
Prepare the ISO 13485 certificate, test reports, risk management file, clinical evaluation and English-language IFU.
Confirm the responsibilities, fees, certificate control and exit mechanism of the local agent or authorized representative.
Build a target-country gap assessment table identifying what must be re-tested, translated, notarized or supported by additional declarations.

AIMEILI Perspective

AIMEILI recommends that companies treat Vietnam registration not as a one-off document submission but as an overseas market access program. For companies entering multiple countries, establishing a clear core technical file and evidence matrix first and then converting it to national requirements is usually faster and more stable than patching documentation country by country, and it also supports later changes and renewals more effectively.

From a project management perspective, three things should be controlled early: first, product classification and pathway determination; second, consistency of the documentation evidence chain; third, the regulatory responsibility boundaries of the local partner. If these three are unclear, the project may still go through repeated rounds of deficiency responses, agent communication and post-market maintenance even when the documentation appears substantial.

Frequently Asked Follow-up Questions

Can domestic documentation be used directly for Vietnam registration?

Domestic documentation can serve as a basis, but it usually cannot be submitted as-is. Companies need to adjust the document structure, language, labels, authorization documents and evidence chain in line with local regulatory requirements.

When is the best time to start a gap assessment?

Immediately after the target markets and product list are confirmed. The earlier the gap assessment is completed, the easier it is to schedule additional testing, translation, label adaptation and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent typically participates in registration communication, changes, renewals and post-market event handling. Unclear responsibilities and rights can affect certificate control and the stability of the market afterwards.

Project Execution Recommendations

When executing this type of registration project, companies should maintain a project register that tracks the product list, models and specifications, registration pathway, document owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This makes documentation gaps visible early and helps management judge whether the project will affect launch plans.

Companies that already hold registrations in several countries should also build an evidence reuse matrix, defining which documents can serve as core evidence and which must be reissued or supplemented for a specific country. Labels and IFU, clinical evaluation, risk management, performance verification and quality system certificates in particular must remain version-consistent.

Confirm target markets and the product list.
Complete risk classification and pathway determination.
Build the documentation gap assessment table.
Define the local agent and certificate control arrangements.
Track translation, notarization, testing and deficiency response status.
Assign post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a review perspective, quality system documentation is not an isolated certificate. Regulators usually examine whether the manufacturer name, manufacturing site, product scope, certificate validity period, applicable standards and technical file are consistent with one another. If the scope of the ISO 13485 certificate does not match the devices being filed, or if the manufacturing site, model specifications, IFU version and test reports are inconsistent, a company may be asked for supplementary explanation even when it has prepared a large volume of documents.

Before submission, companies should prepare an evidence consistency checklist that maps product name, model and specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and IFU version and quality system certificate item by item. This step appears basic, but it significantly reduces the likelihood of deficiency letters, particularly for projects filing simultaneously in several GHWP member states or across multiple product families.

Localization and Authorized Representative Responsibilities

Vietnam registration projects usually involve a local agent, authorized representative, importer or registration holder arrangement. Companies need to confirm in advance whether the local partner only submits documentation or also handles regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, IFU and authorization documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative details and after-sales contact information. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization is converting reusable evidence into a submission structure acceptable in the target country rather than writing an isolated new set of documents.

Post-Market Maintenance and Long-Term Planning

Registration approval does not mean compliance work is finished. Companies must also maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance, and subsequently face a disconnect between the certificate and commercial sales when a manufacturing site changes, models are added, the IFU is updated or the agent is replaced.

AIMEILI recommends managing this question within an annual international registration plan: first set target market priorities, then build a reusable documentation package and a country gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value is not only higher registration efficiency in a single country, but also the development of a repeatable global compliance capability that reduces the cost of rebuilding documentation from scratch each time a new market is entered.

Contact AIMEILI

How to Prepare the Registration Dossier for Medical Device Registration in Vietnam